May 29, 2020
Video
David O'Malley, MD, discusses the role of PARP inhibitors in the treatment landscape of ovarian cancer.
August 23, 2018
Video
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.